These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24343741)

  • 1. Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells.
    Minato H; Kurose N; Fukushima M; Nojima T; Usuda K; Sagawa M; Sakuma T; Ooi A; Matsumoto I; Oda M; Arano Y; Shimizu J
    Am J Clin Pathol; 2014 Jan; 141(1):85-93. PubMed ID: 24343741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations.
    Chang S; Oh MH; Ji SY; Han J; Kim TJ; Eom M; Kwon KY; Ha SY; Choi YD; Lee CH; Lee Y; Jung SH
    Pathol Int; 2014 Dec; 64(12):607-12. PubMed ID: 25376377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
    Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
    J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.
    Kuperman M; Florence RR; Pantanowitz L; Visintainer PF; Cibas ES; Otis CN
    Diagn Cytopathol; 2013 Feb; 41(2):131-40. PubMed ID: 23002041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations.
    Lee AF; Gown AM; Churg A
    Am J Surg Pathol; 2013 Mar; 37(3):421-6. PubMed ID: 23108021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
    Üçer Ö; Dağli AF; Kiliçarslan A; Artaş G
    Turk Patoloji Derg; 2013; 29(2):94-100. PubMed ID: 23661345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
    Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
    Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of immunocytochemistry in differential diagnosis of gastric adenocarcinoma, reactive mesothelial cells and malignant epithelial mesothelioma in metastatic effusion fluid].
    Lyu M; Cha N; Zou YF; Leng JH; Xu L; Sun Y; Hao YY
    Zhonghua Bing Li Xue Za Zhi; 2018 Mar; 47(3):180-185. PubMed ID: 29534357
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia.
    Kushitani K; Amatya VJ; Mawas AS; Miyata Y; Okada M; Takeshima Y
    Pathobiology; 2016; 83(1):33-40. PubMed ID: 26735863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
    Hasteh F; Lin GY; Weidner N; Michael CW
    Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.
    Attanoos RL; Griffin A; Gibbs AR
    Histopathology; 2003 Sep; 43(3):231-8. PubMed ID: 12940775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
    Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
    Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.
    Hui S; Guo-Qi Z; Xiao-Zhong G; Chun-Rong L; Yu-Fei L; Dong-Liang Y
    Hum Pathol; 2018 Nov; 81():138-147. PubMed ID: 30031101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
    Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
    Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
    Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
    Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
    Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
    Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD146 and insulin-like growth factor 2 mRNA-binding protein 3 predict prognosis of asbestos-induced rat mesothelioma.
    Okazaki Y; Nagai H; Chew SH; Li J; Funahashi S; Tsujimura T; Toyokuni S
    Cancer Sci; 2013 Aug; 104(8):989-95. PubMed ID: 23621518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesothelial proliferations: useful marker is not the same as a diagnostic one.
    Husain AN
    Am J Clin Pathol; 2014 Feb; 141(2):152-3. PubMed ID: 24436261
    [No Abstract]   [Full Text] [Related]  

  • 19. Measurement of telomere length in cells from pleural effusion: Asbestos exposure causes telomere shortening in pleural mesothelial cells.
    Aida S; Aida J; Naoi M; Kato M; Tsuura Y; Natsume I; Takubo K
    Pathol Int; 2018 Sep; 68(9):503-508. PubMed ID: 30098092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD146 immunohistochemical staining for the separation of benign from malignant mesothelial proliferations.
    Salisbury T; Churg A
    Virchows Arch; 2021 Nov; 479(5):1047-1050. PubMed ID: 33721119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.